850421-08-8

Basic information

• Product Name: 1-(5-broMo-3-chloropyrazin-2-yl)hydrazine
• Synonyms: 1-(5-broMo-3-chloropyrazin-2-yl)hydrazine;(5-Bromo-3-chloropyrazin-2-yl)hydrazine, 5-Bromo-3-chloro-2-hydrazino-1,4-diazine;5-Bromo-3-chloro-2-hydrazinopyrazine;5-bromo-3-chloro-2-hydrazinylpyrazine(WX191370)
• CAS NO: 850421-08-8
• Molecular Formula: C₄H₄BrClN₄
• Molecular Weight: 223.45836
• Mol File: 850421-08-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(5-broMo-3-chloropyrazin-2-yl)hydrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-broMo-3-chloropyrazin-2-yl)hydrazine(850421-08-8)
• EPA Substance Registry System: 1-(5-broMo-3-chloropyrazin-2-yl)hydrazine(850421-08-8)

Safety Data

• Hazardous Substances Data: 850421-08-8(Hazardous Substances Data)

Usage

General Description

1-(5-bromo-3-chloropyrazin-2-yl)hydrazine is a chemical compound that is a hydrazine derivative with a pyrazine ring structure substituted with bromine and chlorine atoms at specific positions. It is a heterocyclic compound and has potential applications in organic synthesis and medicinal chemistry. The presence of bromine and chlorine atoms can impart specific reactivity and properties to the compound, making it useful for various chemical reactions and processes. Its specific uses and potential effects depend on the context and the specific application in which it is utilized.

Upstream product

• 850421-07-7 N'-(5-bromo-3-chloropyrazin-2-yl)-2,2,2-trifluoroacetohydrazide 

Downstream Products

• 1610045-39-0 6-bromo-8-chloro-3-methyl-[1,2,4]triazolo[4,3-a]pyrazine 
• 1334135-75-9 6-bromo-8-chloro-[1,2,4]triazolo[4,3-a]pyrazine 

Relevant articles and documents

COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA

The present invention relates to the use of volasertib, or a pharmaceutically acceptable salt thereof or a hydrate thereof, in combination with a BET inhibitor, or a pharmaceutically acceptable salt thereof or a hydrate thereof for treating patients suffering from acute myeloid leukemia (AML).

TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS

The present invention provides triazolopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

TRIAZOLOPYRAZINE DERIVATIVES AS BRD4 INHIBITORS

The present invention encompasses compounds of general formula (I), wherein the groups R1 to R3, X3 to X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitab